Unlimited.1InvestorRelationsChairmanChairmanoftheoftheManagingManagingBoardBoardLondonLondon,,FebruaryFebruary18,200218,2002InvestorRelationsUnlimited.1InvestorRelationsHighlightsHighlights20022002��DSMDSMgrantedRoyalgrantedRoyalstatusinstatusincentennialyearcentennialyear��DSM“DSM“DreamActionDreamAction””��SHErecordimprovedSHErecordimproved��DSMDSMshareoutperformershareoutperformerononstockmarketsstockmarketsStrategichighlightsStrategichighlights��DivestmentDivestmentofofDSDSMMPetrochemicalsPetrochemicalstotoSABICSABIC��AcquisitionAcquisitionofofRocheVC&FCRocheVC&FC��~~€€500m500minvestedinvestedininspecialtyportfoliospecialtyportfolioUnlimited.1InvestorRelationsKeyfiguresKeyfigures20022002••EBIT2002EBIT2002fromongoingactivitiesfromongoingactivitiesup14%up14%yearyear--onon--yearyear––EBITEBITfromongoingactivitiesfromongoingactivities:€383:€383millionmillion––EBITDAEBITDAongoingactivitiesongoingactivities:€767:€767millionmillion,,upup4%y.o.y.4%y.o.y.••NetNetsalessalesofofongoingactivitiesongoingactivities:€5,636:€5,636millionmillion,,--2%y.o.y.2%y.o.y.••AutonomousvolumeAutonomousvolumegrowthgrowth:6%:6%––AutonomousvolumeAutonomousvolumegrowthgrowthofofDSM’songoingactivitiesDSM’songoingactivitiesinthelast3inthelast3yearsyearswas5%perwas5%perannumannumononaverageaverage••R&DR&Dexpenditureexpenditure~5%ofnet~5%ofnetsalessales••DividendDividendunchangedunchanged:€1.75per:€1.75perordinaryshareordinaryshareUnlimited.1InvestorRelationsBalanceBalancesheetsheethighlightshighlights0.500.500.580.58••SolvencySolvencyratioratio10.710.763.763.7••EBITDAinterestEBITDAinterestcoveragecoverage5%5%8,5758,5758,9968,996BalanceBalancesheetsheettotaltotal0.170.17n.a.*n.a.*••NetNetdebtdebt//capitalizationcapitalization((--867)867)1,0381,038Netsurplus(Netsurplus(orordebtdebt))--21%21%5,7635,7634,5704,570CapitalemployedCapitalemployed%%2001200120022002((€€million)million)**duetoduetonetsurplusultimo2002netsurplusultimo2002Unlimited.1InvestorRelationsLifeScienceProductsLifeScienceProducts2%2%376376382382EBITDAEBITDA1%1%230230232232EBITEBIT--3%3%2,2372,2372,1682,168NetNetsalessales%%2001200120022002((€€million)million)�Backloginglobalpharma;DPIfullyontrack�DSMAnti-InfectivesgoodresultsdespiteweakUSdollar�DSMBiologicsexpandstechnologyviaCrucellallianceUnlimited.1InvestorRelationsPerformancePerformanceMaterialsMaterials--3%3%204204197197EBITDAEBITDA1%1%112112113113EBITEBIT--5%5%1,8551,8551,7671,767NetNetsalessales%%2001200120022002((€€million)million)�Resiliencedespiteadverseendmarketconditions�DSMDesotechsufferingfromcrisisintelecom�Dyneemasalesboostedby~30%Unlimited.1InvestorRelationsIndustrialIndustrialChemicalsChemicals2%2%155155158158EBITDAEBITDA20%20%64647777EBITEBIT--3%3%1,3021,3021,2681,268NetNetsalessales%%2001200120022002((€€million)million)�DSMFibreIntermediatesstrongimprovement�DSMMelaminemaintainedgood2001level�DownturninfertilizersUnlimited.1InvestorRelationsOutlookOutlookUncertaingeneraleconomicoutlookfor2003:lowGPDgrowth,politicaltensions,risingrawmaterialcost,andaweakeningUSdollarSignificantimprovementofmarketconditionsunlikelybeforeH22003LSPoperatingprofit2003:~2002;H2>H1GivenunusualcombinationofuncertaintiesnofurtherprofitforecastUnlimited.1InvestorRelationsVISION2005�Acceleratedexpansionofspecialtiesportfolio�D...
